Binex announced on the 8th that it has signed a contract worth 20.8 billion won for the manufacturing and supply of biopharmaceuticals with global corporations. Binex is engaged in contract manufacturing of biopharmaceuticals (CMO) with its predecessor, Suncheon Dang Pharmaceuticals.
The scale of this contract corresponds to approximately 16% of the company's revenue last year. The contract period is from Dec. 1 to June 30, 2027. The counterparty has not been disclosed.
Binex also signed a biopharmaceutical manufacturing and supply contract worth 16.2 billion won with a global pharmaceutical company last June. Binex noted, "The contract period may be changed by mutual agreement as production progresses."
※ This article has been translated by AI. Share your feedback here.